Conclusions:
In this prospective observational registry, the cost per TLR avoided with EES was Ͻ$10,000. With the advent of generic thienopyridine availability, the cost effectiveness profile shifts significantly in favor of EES, with similar 1-year aggregate costs compared to BMS.
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Clinical 
Conclusions:
In this large, multicenter, real-world study of Chinese population with complex lesion subsets, XIENCE V demonstrated low rates of ST, TLR and TVF at 30-day. Long-term results will document the safety and effectiveness of XIENCE V in high risk cohorts with long lesion and small vessel/multivessel disease from clinical settings in China. 6-month results will be available at TCT Miami.
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Two-Year Outcomes after Implantation of XIENCE PRIME and XIENCE PRIME Long Lesion Stents 
Background:
The SPIRIT PRIME trial demonstrated the clinical equivalence of the next generation XIENCE PRIME everolimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) to the XIENCE V EES at 1 year. Longer-term outcomes with the XIENCE PRIME stent have not been investigated. Methods: SPIRIT PRIME, a prospective, pivotal, non-randomized clinical trial with two separate arms, tested the XIENCE PRIME in both core size (CSR) and long length (LLR) (33 and 38 mm) stent registries. The CSR analyzed 401 patients and the LLR 104 patients. Treatment of up to 2 de novo lesions in different epicardial vessels was allowed. The primary endpoint was 1-year target lesion failure (TLF; cardiac death, target vessel myocardial infarction [TV-MI] or clinically indicated target lesion revascularization [CI-TLR]) compared to pre-specified performance goals based on historical data and in accordance with FDA requirements. Data were fully monitored and all endpoint events adjudicated by an independent clinical events committee. Results: There were 447 target lesions treated in the CSR and 124 in the LLR. Clinical device success rates were 98.2% in the CSR and 97.6% in the LLR. Female and diabetic subjects were 29.7% and 34.9% in the CSR and 37.5% and 35.6%, in the LLR, respectively. Elderly subjects (Ն65 years old) comprised 41.6% of the CSR and 46.2% of the LLR. The Notes: -N is the total number of subjects.
-Population for SPIRIT PRIME consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8 hours post index procedure and hospital discharge.
-TLF includes cardiac death, target vessel MI or clinically indicated TLR.
-Time frame includes follow-up window (1-year: 365 Ϯ 28 days, 2-year: 730 Ϯ 28 days).
-TLF from hierarchical counts; other outcomes from non-hierarchical counts.
-WHO: World Health Organization.
-ARC: Academic Research Consortium.
Conclusions:
The SPIRIT PRIME study demonstrated sustained 2-year safety and efficacy of the new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in both core size and long lesion cohorts and no new ARC definite/probable ST events in either arm. Background: This study was sought to investigate the impact of complete revascularization (CR) vs. incomplete revascularization (IR) on long-term outcomes in patients with multivessel coronary disease (MVD) in current practice of percutaneous coronary intervention (PCI). Methods: Between April 2004 and November 2010, 7376 consecutive patients with MVD underwent PCI at our center. Patients who underwent prior CABG and those who had an acute myocardial infarction (MI) within 24 hours before revascularization or presented with cardiogenic shock were excluded. Results: Among 7065 patients with MVD undergoing PCI treatment, angiographic CR was performed in 1188 patients (16.8%), and proximal CR in 2053 patients (29.1%). The study found that either angiographic or proximal IR were associated with significantly higher estimated 3-year rate of cardiac death (2.55% vs. 1.13%, log-rank pϭ0.016; and 2.70% vs. 1.43%, log-rank pϭ0.024; respectively). After adjustment for differences in baseline characteristics between IR and CR patients, angiographic IR was associated with a significantly higher rate of cardiac death (adjusted hazards ratio [HR] Background: PCI stent inflation pressure correlates to angiographic lumen improvement and stent expansion but the relation to outcome is not clarified. Using comprehensive registry data our aim was to evaluate how stent inflation pressure influences restenosis and stent thrombosis following PCI. Methods: We evaluated all consecutive coronary stent implantations in Sweden from January 1, 2008, to October 26, 2011 using data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). We used logistic regression and Cox proportional hazard modeling to estimate risk of outcomes with different balloon pressures. Results: In total, 93 697 stents were eligible for analysis and divided into five different pressure interval groups: Յ15 atm, 16-17 atm, 18-19 atm, 20-21 atm and Ն22 atm. The risks of stent thrombosis ( Fig.) and restenosis were significantly higher in the Յ15 atm, 18-19 atm and Ն22 atm groups (but not in the 16-17 atm group) compared to the 20-21 atm group. Post-dilatation was associated with a higher restenosis risk ratio (RR) of 1.22 (95% confidence interval (CI) 1.14-1.32, PϽ0.001) but stent thrombosis did not differ statistically between procedures with or without post-dilatation. Conclusions: Our retrospective study identified a possible optimal stent inflation pressure of 20-21 atm during PCI which was associated with a lower risk of stent thrombosis and restenosis. Post-dilatation might increase restenosis risk. 
TCT-609

Abstract Withdrawn
TCT-610
Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease
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Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions
